Evidence mapPaperPMID 41812012Full record

ArticleOncology nursing forum2026

Investigation of a Mobile, Digital Application to Objectively Assess Cognitive Function in Cancer Survivors.

Jamie S Myers, Sridhar Ramakrishnan, Lisa Scott Holt, Arash Asher

Abstract read
In one paragraph

Article in Oncology nursing forum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jamie S MyersJamie S. Myers.
Sridhar RamakrishnanSridhar Ramakrishnan.
Lisa Scott HoltLisa Scott Holt.
Arash AsherArash Asher.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo demonstrate feasibility of the MindCap mobile, digital application for objective and repeated assessment of cognitive function in cancer survivors and assess its sensitivity to cognitive improvement. SAMPLE &

setting57 adults with stage I-III solid tumors or lymphoma who reported cognitive issues six months to five years postchemotherapy. METHODS & VARIABLES: Participants completed three phases of MindCap testing sessions over 14 weeks. Pre-/postintervention data were collected for time and number of MindCap sessions completed for each phase, adherence to required testing frequency, participant satisfaction, self-report, and MindCap metrics for cognitive domain-specific performance (executive function, attention, memory, verbal ability, visual-spatial ability, and psychomotor function).

resultsFeasibility was demonstrated for recruitment and adherence to MindCap use. Self-report and MindCap metrics correlated positively. MindCap performance metrics were sensitive to improvements in multiple cognitive domains. Post facto analyses indicated a potential MindCap dose effect for cognitive function improvement. IMPLICATIONS FOR NURSING: Future research comparing MindCap metrics to standard neurocognitive testing and investigation for potential dose effect are warranted.

Indexed as

Cancer SurvivorsCognitionCognition DisordersCognitive DysfunctionMobile ApplicationsNeoplasmsAdultAgedFeasibility StudiesFemaleHumansMaleMiddle AgedNeuropsychological Testscancer treatment–related cognitive impairmentcognitive functionneurocognitive testing

Identifiers

PMID41812012
PMCPMC12999056

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.